Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 449

1.

Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.

Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, Dafou D, Sims AH, Gayther SA.

Carcinogenesis. 2011 Oct;32(10):1540-9. doi: 10.1093/carcin/bgr140. Epub 2011 Aug 22.

2.
3.

Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.

Lawrenson K, Mhawech-Fauceglia P, Worthington J, Spindler TJ, O'Brien D, Lee JM, Spain G, Sharifian M, Wang G, Darcy KM, Pejovic T, Sowter H, Timms JF, Gayther SA.

Int J Cancer. 2015 Oct 15;137(8):1806-17. doi: 10.1002/ijc.29197. Epub 2015 Jul 2.

PMID:
25204737
4.

Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.

Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS.

Oncogene. 2011 Aug 11;30(32):3522-36. doi: 10.1038/onc.2011.70. Epub 2011 Mar 21.

5.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

6.
7.

Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.

Steffensen KD, Waldstrøm M, Grove A, Lund B, Pallisgård N, Jakobsen A.

Int J Gynecol Cancer. 2011 Dec;21(9):1592-600. doi: 10.1097/IGC.0b013e31822a0f6b.

PMID:
21926912
8.

Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.

Monticone M, Biollo E, Maffei M, Donadini A, Romeo F, Storlazzi CT, Giaretti W, Castagnola P.

Mol Cancer. 2008 Dec 16;7:92. doi: 10.1186/1476-4598-7-92.

9.

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB.

Cancer. 2013 Feb 1;119(3):548-54. doi: 10.1002/cncr.27782. Epub 2012 Aug 28.

10.

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Nodin B, Zendehrokh N, Sundström M, Jirström K.

Diagn Pathol. 2013 Jun 25;8:106. doi: 10.1186/1746-1596-8-106.

11.

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH.

Clin Cancer Res. 2005 Sep 1;11(17):6116-26.

12.

Expression of BRAF V600E mutant protein in epithelial ovarian tumors.

Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, Schoppmann SF, von Deimling A, Birner P.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):159-64. doi: 10.1097/PAI.0b013e31825d7402.

PMID:
22820660
13.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
14.
15.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549
16.

An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.

Pinciroli P, Alberti C, Sensi M, Canevari S, Tomassetti A.

BMC Genomics. 2013 Jul 26;14:508. doi: 10.1186/1471-2164-14-508.

17.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

18.

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

Peng DX, Luo M, Qiu LW, He YL, Wang XF.

Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

19.

Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.

Shimogai R, Kigawa J, Itamochi H, Iba T, Kanamori Y, Oishi T, Shimada M, Sato S, Kawaguchi W, Sato S, Terakawa N.

Int J Gynecol Cancer. 2008 May-Jun;18(3):499-505. doi: 10.1111/j.1525-1438.2007.01055.x.

PMID:
18476949
20.

Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.

Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X.

Oncol Rep. 2015 Mar;33(3):1235-42. doi: 10.3892/or.2015.3723. Epub 2015 Jan 15.

PMID:
25592872
Items per page

Supplemental Content

Write to the Help Desk